Opinion|Videos|January 21, 2026
Other Key Mantle Cell Lymphoma Highlights From ASH 2025
Author(s)Luhua (Michael) Wang, MD, Nakhle Saba, MD
Michael Wang, MD, and Nakhle Saba, MD, highlight other key mantle cell lymphoma data presented at the 2025 ASH Annual Meeting and Exposition.
Advertisement
Episodes in this series
Michael Wang, MD, and Nakhle Saba, MD, highlight additional mantle cell lymphoma data presented at the 2025 ASH Annual Meeting and Exposition. They discuss notable trial updates, novel agents, and evolving therapeutic approaches. Wang and Saba place these findings in context of the rapidly evolving mantle cell lymphoma treatment landscape.
Advertisement
Related to this article
In TASKIN, the 12-month OS rate was 61.3% with vilamakitug vs 55.7% with placebo plus trifluridine/tipiracil.
The 510(k) clearance covers an MRI-derived AI risk score for stage I to IIIA disease; the high-risk category carried an HR of 2.81 for recurrence.
The FDA has approved dostarlimab for MSI-H or dMMR locally advanced rectal cancer.
The FDA accepted an NDA for UGN-103 for recurrent low-grade intermediate-risk NMIBC, with a target action date of June 14, 2027.
Ulrich Steidl, MD, PhD, has finalized his Montefiore Einstein Comprehensive Cancer Center senior leadership team.
The CirCLIQ Injector approval for subcutaneous isatuximab in multiple myeloma is the first anticancer treatment delivered via an on-body injector in Japan.
The top 5 OncLive TV videos of the week cover insights in multiple myeloma, HR+ breast cancer, CAR T-cell therapy, CLL, and oral SERDs.
Moh’d Khushman, MD, discusses INCA33890’s mechanism of action, phase 1 safety and efficacy data, and the design of NEXERA-303 in MSS colorectal cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Dostarlimab for dMMR/MSI-H Locally Advanced Rectal Cancer
2
FDA Clears TumorSight Risk, an MRI-Derived AI Recurrence Tool for HR+, HER2– Breast Cancer
3
Vilamakitug Meets OS Threshold in Phase 1/2 Refractory mCRC Trial
4
Dr Cercek on the FDA Approval of Dostarlimab for dMMR/MSI-H Locally Advanced Rectal Cancer
5